Acurx Pharmaceuticals (NASDAQ:ACXP) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Acurx Pharmaceuticals (NASDAQ:ACXP) from a sell rating to a hold rating in a report issued on Sunday morning.

A number of other research firms have also recently commented on ACXP. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Acurx Pharmaceuticals in a report on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Trading Down 7.8%

Shares of ACXP opened at $3.19 on Friday. Acurx Pharmaceuticals has a 12-month low of $3.17 and a 12-month high of $25.00. The firm has a market capitalization of $6.67 million, a P/E ratio of -0.37 and a beta of -1.25. The firm has a 50-day moving average price of $4.50 and a 200 day moving average price of $5.96.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its earnings results on Wednesday, November 12th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.38. Equities research analysts predict that Acurx Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Acurx Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned 70.13% of Acurx Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).